Evaluation of photodynamic therapy (PDT) procedures using microfluidic system

A hybrid PDMS/glass microfluidic system for evaluation of the efficiency of photodynamic therapy is presented. 5-aminolevulinic acid (ALA) was used as a precursor of photosensitizer. The geometry of the microdevice presented in this paper enables to test different concentrations of the photosensitizer in a single assay. The viability of the A549 cells was determined 24 h after PDT procedure (irradiation with light which induced a photosensitizer accumulated in carcinoma cells, λ = 625 nm). The presented results confirmed the possibility to perform the photodynamic therapy process in vitro in microscale and the possibility to assess its effectiveness. Moreover, because two identical microstructures on a single chip were performed, the microchip can be used for examination simultaneously various cell lines (carcinoma and normal) or various photosensitizers.     

血清一阶导数荧光光谱诊断早期恶性肿瘤

利用Wistar大鼠接种恶性肉瘤模拟人患上癌症。取Wistar大鼠眼静脉血制备血清,并用乙醇简单处理得上层清液,扫描获得其一阶导数荧光光谱,确定上层清液原卟啉发射带(630 nm附近)的峰高,观察到健康Wistar大鼠与癌变大鼠的血清样存在明显差异,10例癌变样假阳性率为0,而20例正常样中仅有1例假阳性达到了恶性肿瘤早期诊断的目的。     

Oscillatory expression and variability in p53 regulatory network

The effect of delay, nonlinearity and noise on oscillatory motion is of permanent interest for theoretical and experimental research. Here we explore a negative feedback loop between p53 and Mdm2 with a time delay, which is a key circuit in the response of cells to damage. This circuit shows noisy sustained oscillations in individual human cells following DNA damage, and damped oscillations at the cell population level. We demonstrate the effect of delay on the oscillation, and the correlation in time course. In a multi-species system, the events at different time points which span a time delay are coupled even when the delay is large compared with the other characteristic times of the system. We also clarify that the dynamics at the single-cell level appears to be coherent resonance, and the origin of the damped oscillation at the macroscopic level out of the sustained ones at the single-cell level can be ascribed to the dephasing process which is induced by the interplay between nonlinearity and noise. The findings are consistent with experimental observations and advance our understanding of the dynamics of the p53 network.     

Identifying mutated driver pathways in cancer by integrating multi-omics data

Since the driver pathway in cancer plays a crucial role in the formation and progression of cancer, it is very imperative to identify driver pathways, which will offer important information for precision medicine or personalized medicine. In this paper, an improved maximum weight submatrix problem model is proposed by integrating such three kinds of omics data as somatic mutations, copy number variations, and gene expressions. The model tries to adjust coverage and mutual exclusivity with the average weight of genes in a pathway, and simultaneously considers the correlation among genes, so that the pathway having high coverage but moderate mutual exclusivity can be identified. By introducing a kind of short chromosome code and a greedy based recombination operator, a parthenogenetic algorithm PGA-MWS is presented to solve the model. Experimental comparisons among algorithms GA, MOGA, iMCMC and PGA-MWS were performed on biological and simulated data sets. The experimental results show that, compared with the other three algorithms, the PGA-MWS one based on the improved model can identify the gene sets with high coverage but moderate mutual exclusivity and scales well. Many of the identified gene sets are involved in known signaling pathways, most of the implicated genes are oncogenes or tumor suppressors previously reported in literatures. The experimental results indicate that the proposed approach may become a useful complementary tool for detecting cancer pathways.     

Synthesis,anticancer activity,toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine—(thio)urea hybrids as potential kinase inhibitors

Thirty-two novel urea/thiourea compounds as potential kinase inhibitor were designed, synthesized and evaluated for their cytotoxic activity on breast (MCF7), colon (HCT116) and liver (Huh7) cancer cell lines. Compounds 10, 19 and 30 possessing anticancer activity with IC₅₀ values of 0.9, 0.8 and 1.6 μM respectively on Huh7 cells were selected for further studies. These hit compounds were tested against liver carcinoma panel. Real time cell electronic sensing assay was used to evaluate the effects of the compounds 10, 19 and 30 on the growth pattern of liver cancer cells. Apoptotic cell death and cell cycle analysis upon treatment of liver carcinoma cells with hit compounds were determined. A significant apoptotic cell death was detected upon treatment of Huh7 and Mahlavu cells with compound 30 after 48 h of treatment. Additionally, compound 10 caused cell cycle arrest at G0/G1 phase. Mutagenicity of hit compounds was evaluated. Assertively, these compounds were not found to be mutagenic on Salmonella typhimurium strains TA98 and TA100. To understand the binding modes of the synthesized compounds, molecular docking studies were performed using the crystal data of VEGFR and Src-kinase enzymes in correlation with anticancer activities.     

Towards dynamic control of magnetic fields to focus magnetic carriers to targets deep inside the body

Magnetic drug delivery has the potential to target therapy to specific regions in the body, improving efficacy and reducing side effects for treatment of cancer, stroke, infection, and other diseases. Using stationary external magnets, which attract the magnetic drug carriers, this treatment is limited to shallow targets (<5 cm below skin depth using the strongest possible, still safe, practical magnetic fields). We consider dynamic magnetic actuation and present initial results that show it is possible to vary magnets one against the other to focus carriers between them on average. The many remaining tasks for deep targeting in-vivo are then briefly noted.     

Using a partially observable Markov chain model to assess colonoscopy screening strategies – A cohort study

Colorectal cancer (CRC) is notoriously hard to combat for its high incidence and mortality rates. However, with improved screening technology and better understanding of disease pathways, CRC is more likely to be detected at early stage and thus more likely to be cured. Among the available screening methods, colonoscopy is most commonly used in the U.S. because of its capability of visualizing the entire colon and removing the polyps it detected. The current national guideline for colonoscopy screening recommends an observation-based screening strategy. Nevertheless, there is scant research studying the cost-effectiveness of the recommended observation-based strategy and its variants. In this paper, we describe a partially observable Markov chain (POMC) model which allows us to assess the cost-effectiveness of both fixed-interval and observation-based colonoscopy screening strategies. In our model, we consider detailed adenomatous polyp states and estimate state transition probabilities based on longitudinal clinical data from a specific population cohort. We conduct a comprehensive numerical study which investigates several key factors in screening strategy design, including screening frequency, initial screening age, screening end age, and screening compliance rate. We also conduct sensitivity analyses on the cost and quality of life parameters. Our numerical result demonstrates the usability of our model in assessing colonoscopy screening strategies with consideration of partial observation of true health states. This research facilitates future design of better colonoscopy screening strategies.     

Multistep synthesis and screening of heterocyclic tetrads containing furan,pyrazoline, thiazole and triazole (or oxadiazole) as antimicrobial and anticancer agents

In the present study novel heterocyclic tetrads containing furan, pyrazoline, thiazole and triazole (or oxadiazole) (1, 2, 3, 4a-e and 5a-e) were designed and synthesized and investigated for their antimicrobial (against selected bacteria and fungi) and anticancer potential. The molecules 4e and 5e containing 4-fluoro phenyl and 4-fluoro benzyl substituents showed promising antimicrobial (antibacterial and antifungal activities with MICs ranging between 0.5 and 8 µg/mL. Compounds 3 exhibited potent anticancer activity with an IC₅₀ value of 0.49 ± 1.45 µM against the human gastric cancer cell line (BGC-823) whereas compound 4e displayed an IC₅₀ value of 0.65 ± 0.53 µM against breast cancer (MCF-7) cell line respectively. All compounds showed selective toxicity against the cancer cell lines compared to human normal liver cell lines. Molecular docking studies of the most potent compounds (3 and 4e) against selected microbial and cancer proteins revealed the crucial binding interactions of the potent compounds with the target enzymes. Compounds 3 and 4e are promising lead molecules to be developed as potential drug candidates.     

Selective In Situ Analysis of Mature microRNAs in Extracellular Vesicles Using a DNA Cage-Based Thermophoretic Assay

Mature microRNAs (miRNAs) in extracellular vesicles (EVs) are involved in different stages of cancer progression, yet it remains challenging to precisely detect mature miRNAs in EVs due to the presence of interfering RNAs (such as longer precursor miRNAs, pre-miRNAs) and the low abundance of tumor-associated miRNAs. By leveraging the size-selective ability of DNA cages and polyethylene glycol (PEG)-enhanced thermophoretic accumulation of EVs, we devised a DNA cage-based thermophoretic assay for highly sensitive, selective, and in situ detection of mature miRNAs in EVs with a low limit of detection (LoD) of 2.05 fM. Our assay can profile EV mature miRNAs directly in serum samples without the interference of pre-miRNAs and the need for ultracentrifugation. A clinical study showed that EV miR-21 or miR-155 had an overall accuracy of 90 % for discrimination between breast cancer patients and healthy donors, which outperformed conventional molecular probes detecting both mature miRNAs and pre-miRNAs. We envision that our assay can advance EV miRNA-based diagnosis of cancer.